Imelyn Lahey, MD
Family Medicine · Newark, DENPI 1780999300
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 454 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 454 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$1K
- Abbott$717
- Astellas Pharma US Inc$696
- Lilly USA, LLC$685
- Pfizer$661
- plus $3K from 26 others
What the payments were for
- Food & beverage$7,91897%
- Education$2223%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 102 | $1,244 |
| AstraZeneca | 35 | $1,095 |
| Abbott | 25 | $717 |
| Astellas Pharma US Inc | 48 | $696 |
| Lilly USA, LLC | 36 | $685 |
| Pfizer | 44 | $661 |
| GSK | 32 | $617 |
| Boehringer Ingelheim | 32 | $603 |
| Novo Nordisk | 22 | $472 |
| Sanofi-aventis U.S. LLC | 13 | $239 |
| Amgen(2 entities) | 7 | $144 |
| Jazz Pharmaceuticals Inc. | 9 | $116 |
| Idorsia Pharmaceuticals US Inc | 6 | $106 |
| Corium, LLC | 4 | $103 |
| Amarin Pharma, Inc. | 6 | $85 |
| Teva Pharmaceuticals USA, Inc. | 4 | $65 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $60 |
| Avanir Pharmaceuticals, Inc. | 4 | $53 |
| Sumitomo Pharma America, Inc. | 2 | $51 |
| Exact Sciences | 2 | $39 |
| Merck | 2 | $38 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| Medtronic | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $23 |
| Neos Therapeutics, LP | 1 | $22 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| Harmony Biosciences LLC | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,139 in reported general payments places this provider in the 90th percentile of 352 family medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 54 | $75,863 |
| MounjaroTirzepatide | 43 | $55,308 |
| FarxigaDapagliflozin Propanediol | 25 | $33,806 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $30,433 |
| OzempicSemaglutide | 17 | $28,242 |
| MyrbetriqMirabegron | 18 | $23,496 |
| TradjentaLinagliptin | 14 | $19,506 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 12 | $13,341 |
| TrulicityDulaglutide | 11 | $11,735 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $10,991 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $10,670 |
| Spiriva HandihalerTiotropium Bromide | 11 | $10,098 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $5,765 |
| Rosuvastatin Calcium | 300 | $4,920 |
| Atorvastatin Calcium | 359 | $4,680 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr | $603 | $108,71080 claims |
| Lilly USA, LLCMounjaro, Trulicity | $685 | $67,04354 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $617 | $36,19842 claims |
| AstraZenecaFarxiga | $1,095 | $33,80625 claims |
| Novo NordiskOzempic | $472 | $28,24217 claims |
| Astellas Pharma US IncMyrbetriq | $696 | $23,49618 claims |
| MerckJanumet | $38 | $10,99113 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $239 | $10,67011 claims |
| AbbVieSynthroid | $1,244 | $3,19968 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 352 family medicine providers in Delaware.
Other family medicine in Newark
- Michelle PapaNewark$23K
- Ian MyersNewark$17K
- Robert WinterNewark$12K
- Judy LimNewark$12K
- Huy leNewark$10K
- Arlen StoneNewark$10K
- Angela Davis BrownNewark$8K
- Robert CallahanNewark$7K
- George NameyNewark$6K
- William FunkNewark$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.